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Summary
Antiretroviral-naïve adults initiating antiretroviral therapy (ART) in Nairobi, Kenya were tested 
for HIV-1 drug resistance at codons K103N, Y181C, G190A, M184V, and K65R using an 
oligonucleotide ligation assay (OLA). Prevalence of pre-treatment drug resistance (PDR) 
increased from 3.89% in 2006 to 10.93% in 2014 (p<0.001), and 95% of those with resistance had 
at least one non-nucleoside reverse transcriptase inhibitor (NNRTI) mutation. Resistance to 
tenofovir (K65R) was found in 2014 but not in 2006.
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Since the widespread introduction of antiretroviral (ARV) therapy (ART) in sub-Saharan 
Africa there has been concern that HIV-1 drug resistance will become prevalent. Cross-
sectional studies have found varying levels of pre-treatment HIV drug resistance (PDR) 
among ARV-naïve adults that is associated with earlier ART rollout on the continent [1]. 
This study enrolled ARV-naïve adults at two separate time points in 2006 and 2014 at a 
single clinic site in Nairobi, Kenya and measured PDR using an oligonucleotide ligation 
assay (OLA).
Data and specimens were collected from ARV-naïve participants enrolled in two clinical 
trials in 2006 and 2014 at the Coptic Hope Center for Infectious Diseases in Nairobi [2, 3]. 
Sociodemographic information, medical records, and blood samples were analyzed, 
including baseline pre-treatment plasma (2006) and peripheral blood mononuclear cells 
(PBMC) (2014). Following quantification of amplifiable copies of HIV cDNA and DNA by 
realtime PCR [4], ≥100 HIV templates from each participant underwent nested PCR of HIV 
pol to generate amplicons for OLA. OLA examined point mutations at K103N, Y181C, 
G190A, and M184V across all specimens [5]. K65R was evaluated by OLA in 2014 and 
pyrosequencing was performed on enrollment plasma from those with subsequent virologic 
treatment failure in 2006 [4]. The proportion of mutant in each subject’s HIV population 
was quantified by comparing optical densities to standards containing 0%, 2%, 5%, 10%, 
25%, 50%, 75% or 100% mutant, with PDR defined by ≥2% mutant [4].
Wilcoxon rank sum and Chi-square tests were used to compare continuous and categorical 
characteristics. The prevalence of PDR was compared between 2006 and 2014 using Poisson 
regression with robust variance. Stata SE v11 (Statacorp, College Station, TX, USA). The 
study was approved by institutional review boards at the University of Washington (Seattle, 
WA, USA), Seattle Children’s Hospital (Seattle, WA, USA), and Kenyatta National Hospital 
(Nairobi, Kenya).
A total of 953 adults were examined: 386 in 2006 and 567 in 2014. Marital status, number of 
years educated, and age of sexual debut were similar between the two cohorts, and the 
proportion of women in 2006 and 2014 was 66% and 60% respectively. The median age of 
those in 2014 was slightly older than in 2006 (38 vs. 36 years; p<0.01), with higher 
economic status (10% vs. 33% unemployment; p<0.01), better housing (60% vs. 47% flush 
toilet access; p<0.01), fewer lifetime sexual partners (3 vs. 4 partners; p<0.01), and higher 
median CD4 cell count at baseline (198 vs. 115 cells/mL; p<0.01).
The prevalence of PDR was 3.89% [95% Confidence Interval (CI), 2.19%–6.33%] in 2006 
and 10.93% (95% CI, 8.49%–13.80%) in 2014. The unadjusted prevalence of PDR in 2014 
was 2.81 times greater than in 2006 (95% CI, 1.62, 4.87, p<0.001). Adjusting for age, 
gender, marital/attached status, unemployment, lifetime number of sexual partners, travel 
time to clinic, and CD4 count (n=917), the prevalence ratio of PDR was 3.11 (95% CI: 1.69, 
5.73, p<0.001).
In 2006, 24 PDR mutations were detected in 15 participants at baseline (Table 1) [4]. Fifteen 
of the participants had mutations only to NNRTI (K103N, Y181C, G190A), and three had 
mutations to NNRTI plus lamivudine (M184V). The median mutant frequency within a 
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subject’s viral population was 82% (range, 2%–100%). In 2014, 84 mutations were detected 
in 62 participants. Fifty-eight had mutations to NNRTI, two had only lamivudine mutations, 
and two had only tenofovir (K65R) mutations. The median mutant frequency within a 
subject’s viral population was 32% (range 2%–100%).
All ARV-naïve adults with PDR in 2006 and 94% in 2014, had at least one NNRTI mutation 
(overall, 95%). Eighty-seven percent of cases with a lamivudine mutation had a concomitant 
NNRTI and/or tenofovir mutation across both cohorts. Resistance to tenofovir was detected 
in 2014 when it was found in 10% (6 of 62) of those with PDR and 1.1% (6 of 576) of those 
initiating ART (Table 1).
The prevalence of PDR among ARV-naïve adults nearly tripled, rising from 3.9% to 10.9%, 
between 2006 and 2014 in Nairobi, Kenya, and 95% of those with resistance had at least one 
NNRTI mutation. While not found in 2006, PDR to tenofovir was present in 1.1% of all 
individuals initiating ART in 2014, two years after tenofovir replaced stavudine as part of 
first-line ART regimens in Kenya.
This study examined HIV drug resistance among a large sample of ARV-naïve adults across 
nearly a decade. Providing ART at no cost, the clinic attracts a broad patient population from 
diverse sociodemographic backgrounds representative of the capital [6]. The serial nature of 
these data from this large clinic adds a meaningful dimension to previous cross-sectional 
studies [7, 8], and describes significant resistance trends over time, rather than generalizing 
results across East Africa [9].
There are several weaknesses in this study. We did not measure PDR during acute/early HIV 
infection but at ART initiation, and while NNRTI-resistance does not rapidly revert back to 
wild type [10], this study may underestimate resistance, especially the 2006 genotypes from 
plasma. The study only surveyed drug resistant mutations at codons K103N, Y181C, 
G190A, M184V, and K65R, which has the potential to underestimate, not overestimate the 
prevalence of PDR. Testing PDR in PBMC by OLA and defining resistance at ≥2% detects 
mutant frequencies below those discernable by consensus sequencing [11]; however, low 
frequency mutations are associated with greater virologic failure and therefore remain 
clinically relevant [4]. Despite recruitment at one clinic, several sociodemographic 
differences existed between the cohorts and likely reflected Kenya’s economic development. 
While only ARV-naïve adults were examined in this study, previous exposure to ART was 
based on self-report and could be subject to misclassification. Finally, although OLA for 
K65 was not performed among all 386 participants in 2006, pyrosequencing performed on 
the 54 participants with subsequent virologic failure found no K65R in this cohort [4].
In summary, we found that ARV-naïve adults initiating ART in 2014 were three times more 
likely to have PDR than those initiating ART in 2006. This increased prevalence of PDR 
suggests that approximately one out of ten ARV-naïve adults in Kenya could fail their first-
line ART [4].
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Table 1
Prevalence of pre-antiretroviral treatment HIV drug resistance mutations detected by OLA in each 
antiretroviral-naïve adult by cohort year.*
Mutant Codon 2006 (N=386) 2014 (N=567) Total (N=953)
K103N 8 (2.1%) 30 (5.3%) 38 (4.0%)
Y181C 1 (0.3%) 8 (1.4%) 10 (0.9%)
G190A 0 (0%) 3 (0.5%) 3 (0.3%)
M184V 0 (0%) 2 (0.4%) 2 (0.2%)
K65 0 (0%) 2 (0.4%) 2 (0.2%)
K103N + Y181C 0 (0%) 1 (0.2%) 1 (0.1%)
K103N + G190A 1 (0.3%) 5 (0.9%) 6 (0.6%)
K103N + M184V 1 (0.3%) 3 (0.5%) 4 (0.4%)
Y181C + G190A 1 (0.3%) 0 (0%) 1 (0.1%)
Y181C + M184V 0 (0%) 1 (0.2%) 1 (0.1%)
Y181C + K65R 0 (0%) 1 (0.2%) 1 (0.1%)
G190A + M184V 0 (0%) 1 (0.2%) 1 (0.1%)
K103N + Y181C + M184V 2 (0.5%) 2 (0.4%) 4 (0.4%)
K103N + G190A + Y181C 1 (0.3%) 0 (0%) 1 (0.1%)
Y181C + M184V +K65R 0 (0%) 2 (0.4%) 2 (0.2%)
G190A + M184V + K65R 0 (0%) 1 (0.2%) 1 (0.1%)
Total 15 *(3.9%) 62 *(10.9%) 77 (8.1%)
*
Poisson regression with robust standard error estimates comparing 2014 to 2006 found an unadjusted prevalence ratio of 2.81 (95% CI, 1.62, 4.87; 
p<0.001).
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